Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taski-3: Fostamatinib in RA patients who failed biologic therapy
NCT00665626Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- May 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Fostamatinib with Placebo (2 arms). Primary endpoint: American College of Rheumatology 20 Response at 3 months. Started May 2008; status: completed.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00665626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00665626.